SITIO DE TEST - SITIO DE TEST - SITIO DE TEST - SITIO DE TEST - SITIO DE TEST - SITIO DE TEST - SITIO DE TEST - SITIO DE TEST - SITIO DE TEST
 

A Novel Synergistic Combination of Cyclophosphamide and Gene Transfer of Interleukin-12 Eradicates Colorectal Carcinoma in Mice

dc.contributor.authorMalvicini, Mariana
dc.contributor.authorRizzo, Miguel
dc.contributor.authorAlaniz, Laura
dc.contributor.authorPiñero, Federico
dc.contributor.authorGarcía, Mariana
dc.contributor.authorAtorrasagasti, Catalina
dc.contributor.authorAquino, Jorge B.
dc.contributor.authorRozados, Viviana R.
dc.contributor.authorScharovsky, O. Graciela
dc.contributor.authorMatar, Pablo
dc.contributor.authorMazzolini, Guillermo
dc.date.accessioned2012-08-24T17:37:01Z
dc.date.available2012-08-24T17:37:01Z
dc.date.issued2009-11
dc.description.abstractPURPOSE: Interleukin-12 (IL-12) is an immunostimulatory cytokine with potent antitumor effects in several animal models. However, serious toxicity has been associated with its systemic application in humans. Gene transfer has emerged as a tool to specifically express therapeutic genes into the tumor/peritumoral milieu, thus avoiding systemic toxicity. The aim of this study was to analyze whether subtherapeutic doses of an adenovirus encoding IL-12 (AdIL-12) might synergize with low immunopotentiating doses of cyclophosphamide in the treatment of colorectal carcinoma. EXPERIMENTAL DESIGN: The antitumor effect of combining a single low dose of cyclophosphamide with an intratumoral injection of AdIL-12 was evaluated in an in vivo murine colorectal carcinoma model. The immune responses achieved with different treatments were monitored, comparing the effect of combining both therapies with individual treatments. RESULTS: The combined therapy induced a complete tumor regression in >50% of mice in a synergistic fashion, and it significantly prolonged their survival. This strategy was superior to each single treatment in reducing both peripheral and splenic CD4+CD25+Foxp3+ regulatory T cells, increasing the number of activated dendritic cells, and inducing IFN-gamma-secreting CD4-positive T lymphocytes. Importantly, the combined treatment generated a powerful tumor-specific CTL response. Consistently, a significant reduction in IL-10 levels was found. Our data suggest that the combination of nontoxic doses of cyclophosphamide with AdIL-12 allows the generation of good antitumoral responses, thus avoiding undesired side effects of both agents. CONCLUSIONS: Our data strongly support the use of a combination of cyclophosphamide and AdIL-12 as a novel therapeutic strategy against colorectal carcinoma.es
dc.description.peerreviewedPeer reviewedes
dc.description.sponsorshipAgencia Nacional de Promoción Científica y Tecnológica (ANPCyT) grant PICT-2005/34788 (P. Matar, V. Rozados, O.G. Scharovsky and G. Mazzolini); PICTO-CRUP 2005/31179 (G. Mazzolini); AECID 2008 D/022066/08 (G. Mazzolini). LA work is supported in part by Mizutani Foundation. C. Atorrasagasti and M. Malvicini are fellows from ANPCyT.es
dc.formatapplication/pdf
dc.identifier.citationMalvicini, M., Rizzo, M., Alaniz, L., Pinero, F., Garcia, M., Atorrasagasti, C., Aquino, J. B., ... Mazzolini, G. (November 30, 2009). A Novel Synergistic Combination of Cyclophosphamide and Gene Transfer of Interleukin-12 Eradicates Colorectal Carcinoma in Mice. Clinical Cancer Research, 15, 23, 7256-7265es
dc.identifier.issn1078-0432
dc.identifier.urihttp://hdl.handle.net/2133/2009
dc.language.isoenes
dc.publisherAmerican Association for Cancer Researches
dc.relation.publisherversionhttp://clincancerres.aacrjournals.org/content/15/23/7256.fulles
dc.rightsopenAccess
dc.rights.text© American Association for Cancer Researches
dc.subjectCombined immunotherapyes
dc.subjectCyclophosphamide gene therapyes
dc.subjectInterleukin-12es
dc.subjectColorectal carcinomaes
dc.titleA Novel Synergistic Combination of Cyclophosphamide and Gene Transfer of Interleukin-12 Eradicates Colorectal Carcinoma in Micees
dc.typearticle
dc.typeartículo
dc.typepublishedVersion

Archivos

Bloque original
Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
Clin Cancer Res-2009-Malvicini-7256-65.pdf
Tamaño:
548.29 KB
Formato:
Adobe Portable Document Format
Bloque de licencias
Mostrando 1 - 1 de 1
Nombre:
license.txt
Tamaño:
0 B
Formato:
Item-specific license agreed upon to submission
Descripción: